card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Three key decisions cell and gene therapy trial sponsors need to make early into drug development

Three key decisions cell and gene therapy trial sponsors need to make early into drug development
Home / Insights / Three key decisions cell and gene therapy trial sponsors need to make early into drug development

In the rapidly growing and innovative therapeutic area, how do clinical trial sponsors effectively navigate the multitude of unique intricacies involved in cell and gene therapy development? 

In a recent joint thought leadership article for PharmaPhorum, IQVIA experts Patrick Brady and Diego Correa and IQVIA Laboratories' Alan Wookey discuss several noteworthy considerations that impact complex Cell and Gene Therapy (CAGT) development. This can include the coordination and oversight of end-to-end laboratory assessments and evolving regulatory guidance in a fast-paced landscape. 

These experts' collective insights emphasize the importance of accounting for the wide-ranging spectrum of needs for CAGT development and accordingly mapping out key decisions early in the trial planning process